On Monday, Adaptimmune Therapeutics Plc ADR (NASDAQ: ADAP) was -6.10% drop from the session before settling in for the closing price of $0.59. A 52-week range for ADAP has been $0.55 – $2.05.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Annual sales at Healthcare sector company grew by 134.88% over the past five years. When this article was written, the company’s average yearly earnings per share was at 71.06%. With a float of $226.49 million, this company’s outstanding shares have now reached $255.70 million.
Let’s look at the performance matrix of the company that is accounted for 449 employees. In terms of profitability, gross margin is 95.26%, operating margin of -28.14%, and the pretax margin is -28.42%.
Adaptimmune Therapeutics Plc ADR (ADAP) Insider Updates
Also, it is sometimes useful to examine the sentiment of large-scale investors toward Adaptimmune Therapeutics Plc ADR stocks. The insider ownership of Adaptimmune Therapeutics Plc ADR is 11.49%, while institutional ownership is 42.01%. The most recent insider transaction that took place on Jun 18 ’24, was worth 22,814. In this transaction Chief Commercial Officer of this company sold 24,531 shares at a rate of $0.93, taking the stock ownership to the 38,293 shares. Before that another transaction happened on Jan 17 ’24, when Company’s Chief Executive Officer sold 30,080 for $0.67, making the entire transaction worth $20,244. This insider now owns 44,848 shares in total.
Adaptimmune Therapeutics Plc ADR (ADAP) Performance Highlights and Predictions
Wall Street market experts anticipate that the next fiscal year will bring earnings of 0 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 71.06% per share during the next fiscal year.
Adaptimmune Therapeutics Plc ADR (NASDAQ: ADAP) Trading Performance Indicators
You can see what Adaptimmune Therapeutics Plc ADR (ADAP) is doing with its current performance indicators. In the most recent quarter, the stock posted a quick ratio of 3.82. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 0.81.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -0.21, a number that is poised to hit -0.03 in the next quarter and is forecasted to reach -0.08 in one year’s time.
Technical Analysis of Adaptimmune Therapeutics Plc ADR (ADAP)
Adaptimmune Therapeutics Plc ADR (NASDAQ: ADAP) saw its 5-day average volume 3.38 million, a positive change from its year-to-date volume of 1.8 million. As of the previous 9 days, the stock’s Stochastic %D was 27.18%. Additionally, its Average True Range was 0.04.
During the past 100 days, Adaptimmune Therapeutics Plc ADR’s (ADAP) raw stochastic average was set at 0.86%, which indicates a significant decrease from 6.53% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 50.39% in the past 14 days, which was lower than the 75.15% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $0.6905, while its 200-day Moving Average is $1.0122. Nevertheless, the first resistance level for the watch stands at $0.5768 in the near term. At $0.5996, the stock is likely to face the second major resistance level. The third major resistance level sits at $0.6110. If the price goes on to break the first support level at $0.5426, it is likely to go to the next support level at $0.5312. Assuming the price breaks the second support level, the third support level stands at $0.5084.
Adaptimmune Therapeutics Plc ADR (NASDAQ: ADAP) Key Stats
There are 255,883K outstanding shares of the company, which has a market capitalization of 141.76 million. As of now, sales total 60,280 K while income totals -113,870 K. Its latest quarter income was 40,900 K while its last quarter net income were -17,620 K.
